Shilpa Medicare Enters into a Licensing Agreement to Expand Access to Biosimilars Across Latin America

SteinCares and Shilpa Biologicals have entered into a strategic licensing agreement to commercialise a biosimilar across Latin America. Under this partnership, Shilpa Biologicals will handle product development and long-term manufacturing from its facility in Dharwad, India, while SteinCares will hold exclusive rights for registration, distribution and commercialisation throughout the Latin American region.

This collaboration leverages Shilpa’s expertise in biologics development—specifically within immunology, oncology and ophthalmics—and combines it with SteinCares’ established regional platform. By merging technical manufacturing capabilities with deep local market access and regulatory knowledge, the two companies aim to provide patients with more affordable, high-quality treatment options.

The agreement marks a significant milestone as Shilpa Biologicals’ first official entry into the Latin American market. It also reinforces SteinCares' position as a leader in specialty healthcare, expanding its portfolio of cost-effective biosimilars and ensuring broader access to critical biopharmaceuticals for healthcare systems across the continent.

About the Company

Shilpa Medicare Ltd is an Indian pharmaceutical company that specialises in the development, manufacturing and marketing of active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). The company has a global presence, with exports to over 65 countries.

According to the financials, Shilpa Medicare has a market cap of over Rs 6,300 crore. The stock gave multibagger returns of 156 per cent in just 3 years whereas the BSE Sensex Index is 38.5 per cent.

Disclaimer: The article is for informational purposes only and not investment advice.